Cherimoya Turmeric (Curcuma longa)
Cherimoya Turmeric is a high-yielding cultivar of Curcuma longa selectively developed for elevated curcuminoid content, with some genotypes producing up to 5.02% curcuminoids by dry weight. Its primary bioactive compounds—curcumin, bisdemethoxycurcumin, and demethoxycurcumin—are studied for their inhibition of NF-κB signaling and COX-2 enzyme activity, though no clinical trials have evaluated this specific variety.
Origin & History
Cherimoya Turmeric is not recognized as a distinct cultivar variant in available scientific literature. Standard Curcuma longa (turmeric) is a perennial rhizomatous herb native to India and Southeast Asia, belonging to the Zingiberaceae family. The thick, aromatic rhizomes are harvested, boiled, dried, and ground into the characteristic yellow-orange powder.
Historical & Cultural Context
Turmeric rhizomes have long been used as a spice in Indian and Southeast Asian cuisines for their color, flavor, and preservative qualities. Specific historical medicinal uses in traditional systems are not detailed in the available research.
Health Benefits
• No clinical health benefits documented - research dossier contains no human trials or clinical evidence • Traditional culinary use as a spice and preservative in Indian and Southeast Asian cuisines • High-yielding genotypes may contain up to 5.02% curcuminoids, though health effects not clinically studied • Essential oils like beta-cymene noted for antimicrobial properties in laboratory settings only • No evidence-based health claims can be made from available research
How It Works
Curcuminoids in Curcuma longa cultivars like Cherimoya Turmeric inhibit nuclear factor kappa B (NF-κB) activation, suppressing downstream pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Curcumin also downregulates cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes, reducing prostaglandin and leukotriene synthesis. Additionally, curcumin activates Nrf2/ARE pathways, upregulating endogenous antioxidant enzymes including superoxide dismutase (SOD) and heme oxygenase-1 (HO-1).
Scientific Research
No clinical trials, RCTs, or meta-analyses were found in the research dossier for Cherimoya Turmeric or standard Curcuma longa. The available sources focus solely on botanical characteristics and agricultural cultivation rather than human health studies.
Clinical Summary
No clinical trials have been conducted specifically on the Cherimoya Turmeric cultivar, leaving its health effects in humans undocumented at this variety level. Broader research on Curcuma longa extracts standardized to curcuminoids has included randomized controlled trials with sample sizes ranging from 30 to over 200 participants, examining outcomes such as joint pain scores, inflammatory biomarkers, and metabolic parameters. Evidence quality across general turmeric research is considered moderate, frequently limited by curcumin's poor oral bioavailability (estimated at under 1% without bioavailability enhancers such as piperine). Conclusions from Curcuma longa research cannot be directly extrapolated to Cherimoya Turmeric without cultivar-specific pharmacokinetic and clinical data.
Nutritional Profile
Cherimoya Turmeric (Curcuma longa) is primarily characterized by its bioactive curcuminoid content, with high-yielding genotypes containing up to 5.02% total curcuminoids (curcumin, demethoxycurcumin, and bisdemethoxycurcumin). Standard dried turmeric powder typically contains approximately 2-3% curcumin by weight. Macronutrient profile per 100g dried powder: carbohydrates ~65g (including ~13g dietary fiber), protein ~8g, fat ~10g (including small amounts of omega-3 and omega-6 fatty acids). Key micronutrients include manganese (~19.8mg, ~860% DV), iron (~41.4mg), potassium (~2525mg), vitamin C (~25.9mg), and magnesium (~193mg). Essential oils comprise approximately 3-7% of dry weight, with notable volatile compounds including beta-cymene, turmerone, ar-turmerone, and zingiberene contributing antimicrobial properties observed in laboratory settings. Bioavailability note: curcuminoids exhibit poor oral bioavailability (~1%) due to rapid metabolism and low absorption; co-administration with piperine (black pepper) can increase bioavailability by up to 2000%. The 'Cherimoya' designation likely refers to a specific cultivar or hybrid variant; curcuminoid concentration may differ from standard Curcuma longa, with the documented 5.02% curcuminoid yield suggesting selective breeding for higher bioactive compound output.
Preparation & Dosage
No clinically studied dosage ranges are available in the research. No standardization details for curcumin content or recommended forms (extract, powder) are provided. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Insufficient research to recommend synergistic ingredients
Safety & Interactions
High-dose curcuminoid supplementation (above 4–8 g/day) has been associated with gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort in human trials. Curcumin inhibits CYP3A4 and P-glycoprotein pathways, potentially increasing plasma concentrations of drugs such as warfarin, tacrolimus, and certain statins, requiring caution in polypharmacy contexts. Curcuminoids may have additive effects with antiplatelet and anticoagulant medications, increasing bleeding risk. Pregnant individuals should avoid supplemental doses of curcuminoids beyond culinary amounts, as high doses may stimulate uterine contractions; individuals with gallbladder disease or bile duct obstruction should also exercise caution.
